Clinical Trial Update: A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Avapritinib for newly diagnosed KIT-mutant acute myeloid leukemia with t(8;21)(q22;q22) or t(16;16)(p13;q22), currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia with
• Acute Myeloid Leukemia with Inv or

Drugs mentioned

• Avapritinib (avapritinib)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Acute Myeloid Leukemia With T(8;21)(Q22;Q22), Acute Myeloid Leukemia With T(16;16)(P13;Q22) | Phase 1, Phase 2 | Status: RECRUITING